RTP Mobile Logo

Monday, June 4, 2018, Chicago, IL, 6:45 AM – 7:45 AM

Breakfast with the Investigators: Management of Renal Cell Carcinoma

Event Details

Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
Hotel Phone: (312) 922-4400

6:15 AM – 6:45 AM (Central Time) — Registration
6:45 AM – 7:45 AM (Central Time) — Educational Breakfast Meeting

Meeting Room:
Grand Ballroom (Level 2)

There is no registration fee for this event. However, preregistration is advised as seating is limited.  
David F McDermott, MD
Professor of Medicine
Harvard Medical School
Director, Biologic Therapy and Cutaneous
Oncology Programs
Beth Israel Deaconess Medical Center
Leader, Kidney Cancer Program
Dana-Farber Cancer Center
Boston, Massachusetts

Thomas Powles, MBBS, MRCP, MD
Professor of Urology Oncology
Director of St Bartholomew’s Cancer Centre
Queen Mary University of London
London, United Kingdom

David I Quinn, MBBS, PhD
Medical Director, Norris Cancer Hospital and Clinics
Head, GU Cancer Section
Division of Cancer Medicine and Blood Diseases
USC/Norris Comprehensive Cancer Center
Los Angeles, California

Neil Love, MD
Research To Practice
Miami, Florida

Not an official event of the 2018 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO, CancerLinQ, or the Conquer Cancer Foundation.

This activity is supported by educational grants from Bristol-Myers Squibb Company, Eisai Inc and Genentech BioOncology.


Meeting Format and Agenda

This unique activity will feature several distinct content modules during which the faculty will review available data sets, present cases from their practices and provide perspectives on key clinical questions as part of a moderated discussion. The event will not include traditional didactic lectures, and the following topics will be reviewed.

MODULE 1: Current Clinical Considerations in the First-Line Management of Metastatic Renal Cell Carcinoma (mRCC)

  • Patient- and disease-specific factors affecting the selection of first-line therapy for mRCC
  • Design, entry criteria and key efficacy and safety results from the Phase III CheckMate 214 study comparing nivolumab/ipilimumab to sunitinib as first-line treatment of advanced RCC; recent FDA approval of nivolumab with ipilimumab and integration into the treatment algorithm
  • Management of side effects associated with the combination of an anti-PD-1 antibody and an anti-CTLA-4 antibody
  • Available data from the Phase II CABOSUN trial comparing cabozantinib to sunitinib; FDA approval of cabozantinib as first-line therapy for advanced RCC
  • Comparative safety of the approved VEGF-directed tyrosine kinase inhibitors for patients with mRCC

MODULE 2: Management of Relapsed/Refractory Metastatic Disease

  • Clinical considerations in the selection of second-line treatment for patients experiencing disease progression on first-line sunitinib, pazopanib or cabozantinib
  • Impact of the recent FDA approval of front-line nivolumab/ipilimumab on selection and sequencing of therapies for relapsed disease
  • Current clinical role of nivolumab monotherapy in advanced RCC
  • FDA approval of an every 4-week dosing schedule with nivolumab; implications for clinical management and patient follow-up
  • Incidence and recognition of pseudoprogression in patients receiving immune checkpoint inhibitors; frequency and characteristics of pseudoprogression in patients with mRCC versus other solid tumors
  • Potential synergy of anti-VEGF therapy in combination with an mTOR inhibitor; optimal integration of lenvatinib/everolimus into the care of patients with mRCC

MODULE 3: Emerging Immunotherapeutic Combinations for mRCC

  • Biologic rationale for combining immune checkpoint inhibitors with VEGF-directed therapy
  • Design, entry criteria and key efficacy findings from the Phase III IMmotion151 study of atezolizumab in combination with bevacizumab versus sunitinib for untreated advanced RCC
  • Spectrum of toxicities and rates of discontinuation observed with atezolizumab/bevacizumab versus sunitinib in IMmotion151
  • Potential role of atezolizumab/bevacizumab in the management of mRCC
  • Early activity and safety observed with the use of anti-PD-1/PD-L1 antibodies in combination with VEGF-directed tyrosine kinase inhibitors (eg, avelumab/axitinib, pembrolizumab/lenvatinib, pembrolizumab/axitinib)
  • FDA breakthrough therapy designations for avelumab/axitinib and pembrolizumab/lenvatinib; implications for the development of time lines and ongoing research
  • Ongoing Phase III trials evaluating anti-PD-1/PD-L1 antibodies in combination with targeted agents (eg, CLEAR, JAVELIN Renal 101, KEYNOTE-426 trials)

CE Information

Target Audience:
This program is intended for medical oncologists, hematology-oncology fellows and other allied healthcare professionals involved in the treatment of renal cell carcinoma (RCC).

Learning Objectives and Goals:
At the conclusion of this activity, participants should be able to:

  • Appraise recent data on diagnostic and therapeutic advances in RCC, and integrate this information, as appropriate, into current clinical care.
  • Develop an evidence-based approach to the sequencing of systemic therapies for patients with advanced RCC, incorporating tyrosine kinase inhibitors, anti-VEGF antibodies, mTOR inhibitors and immunotherapeutic agents.
  • Appreciate the recent FDA approval of nivolumab in combination with ipilimumab as front-line treatment for intermediate- and poor-risk advanced RCC, and develop strategies to optimally integrate these agents into the clinical care of patients.
  • Recognize toxicities attributable to diverse systemic treatments for RCC, and offer preventive or emergent interventions to minimize or ameliorate these side effects.
  • Appraise emerging clinical trial data evaluating anti-PD-1/PD-L1 antibodies in combination with other immunotherapeutic or targeted agents for previously untreated or relapsed metastatic RCC, and prepare for the potential availability of these approaches in routine practice.
  • Recall available and emerging data with other investigational agents and strategies currently in testing for RCC and, where applicable, refer eligible patients for trial participation or other expanded access programs.

CME Credit Form:
A CME credit form will be given to each participant at the conclusion of the activity.

Accreditation Statement:
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement:
Research To Practice designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Policy:
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided in meeting course materials.

This activity is supported by educational grants from Bristol-Myers Squibb Company, Eisai Inc and Genentech BioOncology.


Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
Hotel Phone: (312) 922-4400

Meeting Room:
Grand Ballroom (Level 2)

The Hilton Chicago hotel is located just 5 minutes (2.5 miles) north of the McCormick Place convention center.



Thank you for your interest in our educational program.  At this time, online preregistration is closed. However, seats are still available for the conference. Onsite registration will be open starting at 6:15 AM (Central Time) on Monday, June 4th. If you are interested in attending, please visit our registration desk in the Grand Ballroom foyer located on the second level of the Hilton Chicago (720 Michigan Avenue, Chicago, IL).

Please note, onsite registrant seating will be prioritized for healthcare professionals directly involved in the treatment of patients. If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com or call (800) 233-6153.